Trading Summary - November 1. Another satisfactory

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
222
Trading Summary - November 1.

Another satisfactory status quo day for $DIGX as the countdown to the pre-Q3 loading run continues.

Nobody duped to sell at .0003 or .0004 by the fake stacked ask or the nonsense from the non-credible bashers on iHub.

No attempts at paint downs today.

The whales and many of my followers are still concentrating on loading bottom range prices on 3 other alerted stocks which are likely to run this week or next week.

As has been evident for several weeks now, nobody is going to get any significant amount of .0003s before the next run.

The real ask from MMs other than NITE at .0005 was the same at around 14M. It remains to be see how much of the NITE figure is fake and will be pulled when hit hard. 50M has been bought out before and can be again if necessary.

The visible bid was maintained above 100M all day - peaking at 123M with some cash being taken to buy bottoming stocks elsewhere towards the close as there is almost no chance of any significant fills at .0003 on $DIGX.

Only 9 trading days remain now to the filing of the Q3 Report (due November 15) - with demand-led pre-runs usually happening beforehand.

Stay sharp if you don't already have all the shares you need to make your profit expectations. Prior warning and / or scanner alerts will not be given on iHub.

Content below the line mainly unchanged from last update - relevant to those that are new here.

Those that fail to cancel any sell orders at .0005 can expect to lose their shares within seconds / minutes at some point in the coming days / weeks - with probably the same people buying as prior to Q1 & Q2. Timing is likely to depend on whether other picks common to the main buyers are running or not on any particular day - as several are in the frame over the next 1 to 8 weeks with PRs and filings starting to roll out.

There are at least 4 x whales who trade $DIGX continuously throughout each year who will be happy to take around 20M each if anyone is stupid or impatient enough to sell for a loss at any level below the current one. Any shares bought at .0004 will be worth an easy 150%+ profit on any of numerous runs likely to happen through to Q3 and Q4. Shares bought at .0005 should easily return 100%+ at some point.

In my experience, 70M>100M is the optimum amount to take best advantage of each run whilst keeping the 25M cheapest batches for the bigger runs next year (especially Q4 in March 2018 when the full year profits will be up). My cheapest 25M retained for next year will not require any shares bought above .0004 now so all others will be tradeable for up to 100% during the remaining runs in 2017.

Expect the status quo to be maintained until the next pre-Q3 run, with it making little difference to long-term traders whether shares are picked up at .0004/5/6 - they will see a profit on all of them by Q3 / Q4 and on various runs between. the big boys in DIGX will probably be aiming to have an inventory of 50M>120M (based on near instantaneous loading seen across 2 price points in seconds when coming off the inter-Q bottom before).

Also expect an element of the .0003 bidders - particularly those unlikely to fill on paint downs in the time remaining before the next run prior to Q3 at latest - to continue to buy .0004s and .0005s whilst they are still available. Only 33% of the bid at .0003 hitting the ask at .0005 would be sufficient to take out even the current fake ask if left there.

We can now look forward to additional updates on both the possible merger discussed recently and the implementation of the additional services being offered in the chiropractic chain offices - per the Strategic Growth Plan announced earlier - over the coming days, weeks and months..

The long whales will continue to buy at all prices that makes sense to them at any given point to have a cache for trading on any demand led run, the Q3 and through to the Annual Report in March 2018.

$DIGX will most likely not be allowed to go to previous year-end or inter-Q lows.

In my opinion, nobody has bought $DIGX in 2017 at a price that it isn't likely to exceed in the coming months (2017 high .0013) through to the Annual Report (March 2018).

Ludicrous claims by the notorious bashers currently on iHub - "RFB", "munimi", "Crown Capital" and "surfkast" - are clearly seen as such by all serious traders and now even by most short term (next Q) iHubbers.

Debunking nonsense posted by morons on iHub, there is absolutely no need or intention to do a reverse split. The share structure is exceptionally thin - with no dilution - and the company has been buying back shares. OTC market specialists who trade $DIGX continuously would not be loading 50M>100M shares at these inter-Q bottom prices to trade over the next 6 months if there was even the remote possibility of a reverse split.

Regardless of whether iHub posters lose interest over the coming days and weeks, detailed coverage will continue here as $DIGX remains one of my top picks for repeat profits for those that are patient and trade it to best effect (keep all cheapest batches of shares - create an inventory of shares at higher prices to trade on every run - big or small).

In addition, money is not considered "dead" by the most successful traders in the OTC market when they know it will provide a significant return further down the line because they are in a position to understand and influence - through keen observation and record keeping - what volume of shares is likely to be made available for purchase at any particular level.






American EcoFuels Inc (AEFI) Stock Research Links

AEFI Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Sandler Partners Unveils 2025 Superstar Trip Destination

Updated Category News Views 179

Sandler Partners Unveils 2025 Superstar Trip Destination Sandler Partners is thrilled to reveal the highly anticipated location for its 2025 Superstar Trip, a special reward designed to honor Partners who have excelled in achieving their growth objectives for the year. The trip will take place at the stunning Susurros del Corazón Resort, located along the picturesque...

Continue Reading
e.l.f. Beauty Stock Insights: Understanding Market Trends Today

Updated Category News Views 309

Market Sentiment Surrounding e.l.f. Beauty Investors with substantial capital are showing a cautious approach towards e.l.f. Beauty (NYSE: ELF). This sentiment isn't just noise in the market; it reflects deeper strategies that should be on the radar of traders and analysts alike. There has been significant insight gleaned from public options activity which suggests that...

Continue Reading
Empowering Teens Through Free AI Bootcamp by Mark Cuban

Updated Category News Views 216

Empowering Teens Through Innovative AI Bootcamp Time is of the essence for high school students eager to launch their careers in technology with the Mark Cuban Foundation's Artificial Intelligence (AI) Bootcamp. Hosted by Girls Inc., this remarkable initiative opens doors for teens interested in the cutting-edge realm of AI. Applications for participation are set to close...

Continue Reading
BlackRock's Major Acquisition of Global Infrastructure Partners

Updated Category News Views 275

BlackRock Secures $12.5 Billion Deal The U.S. Federal Energy Regulatory Commission has recently approved BlackRock's substantial acquisition of Global Infrastructure Partners, valued at $12.5 billion. This approval is a pivotal moment for BlackRock as it seeks to broaden its reach within the infrastructure investment sector. Details of the Acquisition In this significant...

Continue Reading
Key Analyst Initiations Impacting Major Stocks This Week

Updated Category News Views 120

Recent Analyst Initiations: An Overview In the dynamic realm of stock trading, the insights of analysts can have a major impact on market trends. Recently, Wall Street has made significant adjustments to their ratings for several well-known stocks. Below, we summarize the latest analyst actions that may affect investor decisions this week. Arm Holdings plc (NASDAQ: ARM)...

Continue Reading